A compound derived from cannabinol (CBN) protected dopamine-producing nerve cells from death in a laboratory model of Parkinson’s disease, according to a study published in ACS Medicinal Chemistry Letters.
Researchers from India’s National Institute of Mental Health and Neurosciences and collaborating institutions examined modified cannabinoids designed to strengthen cellular defenses against oxidative stress. The team used laboratory experiments and computer modeling to evaluate how the compounds interact with Keap1, a protein involved in regulating the antioxidant response controlled by Nrf2.
Among the compounds tested, CS-11 demonstrated the strongest neuroprotective effect, with a half-maximal effective concentration of 100 nanomolar. Treatment significantly increased the activity of cell-protective genes, indicating that it enhanced the antioxidant response regulated by Nrf2.
“CS-11 (4a) also restored tyrosine hydroxylase levels and protected dopaminergic neurons from cell death,” the researchers wrote.
Tyrosine hydroxylase is an enzyme involved in dopamine production. The findings therefore point to both improved cell survival and restoration of a protein important to the function of dopamine-producing neurons.
Computer analyses also supported the compound’s interaction with Keap1. Researchers investigated this target because disrupting its interaction with Nrf2 can strengthen antioxidant defenses, potentially helping cells withstand oxidative stress associated with neurodegenerative disease.
Together, the findings identify CS-11 as a promising candidate for further Parkinson’s research. However, the experiments involved a chemically modified cannabinoid and laboratory testing. Further studies are needed to determine whether its protective effects translate into benefits for people with Parkinson’s disease. The results do not establish that commercially available CBN products produce the same effects.
